These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34737636)

  • 21. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
    Somlo G; Martel CL; Lau SK; Frankel P; Ruel C; Gu L; Hurria A; Chung C; Luu T; Morgan R; Leong L; Koczywas M; McNamara M; Russell CA; Kane SE
    Breast Cancer Res Treat; 2012 Feb; 131(3):899-906. PubMed ID: 22042372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
    Jiang XP; Yang DC; Elliott RL; Head JF
    Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
    Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
    J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer.
    Wu M; Gong J; Yu W; Geng J; Zeng L; Kong X
    J BUON; 2020; 25(4):1814-1820. PubMed ID: 33099918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.
    Kulhari H; Pooja D; Shrivastava S; Kuncha M; Naidu VGM; Bansal V; Sistla R; Adams DJ
    Sci Rep; 2016 Apr; 6():23179. PubMed ID: 27052896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
    Aogi K; Saeki T; Nakamura S; Kashiwaba M; Sato N; Masuda N; Rai Y; Ohno S; Kuroi K; Nishimura R; Miyakoda K; Akiyama F; Kurosumi M; Ikeda T
    Int J Clin Oncol; 2013 Aug; 18(4):598-606. PubMed ID: 22833344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.
    Matsuyama H; Shimabukuro T; Hara I; Kohjimoto Y; Suzuki K; Koike H; Uemura H; Hayashi T; Ueno M; Kodaira K; Tomita Y; Sakurai T; Shimizu N
    Int J Clin Oncol; 2014 Oct; 19(5):946-54. PubMed ID: 24272390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex
    Ghassami E; Varshosaz J; Jahanian-Najafabadi A; Minaiyan M; Rajabi P; Hayati E
    Int J Nanomedicine; 2018; 13():493-504. PubMed ID: 29416331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Factors Contributing to the Occurrence of Edema in Breast Cancer Patients Receiving DTX Treatment].
    Uno K; Takada S; Hashishita H; Endo M
    Gan To Kagaku Ryoho; 2020 Jul; 47(7):1069-1073. PubMed ID: 32668854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
    Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
    Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
    Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel encapsulation in nanoscale assembly micelles of folate-PEG-docetaxel conjugates for targeted fighting against metastatic breast cancer in vitro and in vivo.
    Andisheh F; Oroojalian F; Shakour N; Ramezani M; Shamsara J; Khodaverdi E; Nassirli H; Hadizadeh F; Alibolandi M
    Int J Pharm; 2021 Aug; 605():120822. PubMed ID: 34182039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of some cellular biomarker proteins, oxidative stress and clinical indices as results of laparoscopic appendectomy for perforated appendicitis in children.
    Liu Q; Xu K
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):197-203. PubMed ID: 32538771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.